Hunilife is dedicated to advancing human health through the development of innovative therapeutic antibodies and novel biologics aimed at treating cancer and immune diseases. The company focuses on creating treatments that are globally patented and target hard-to-treat conditions. Their research and development efforts are conducted in collaboration with international professional research institutions, allowing for efficient progression from preclinical trials to human clinical trials. This approach emphasizes the importance of scientific rigor and persistence in the quest for better health outcomes.

One of the key products in Hunilife's pipeline is the Enolase-1 antibody, which is part of an Antibody Drug Conjugate (ADC) platform. This technology combines the targeting capabilities of antibodies with the cytotoxic effects of drugs, enhancing the precision of cancer treatment. Additionally, Hunilife is exploring cell therapy options related to Enolase-1, further expanding their therapeutic arsenal. The company aims to leverage life sciences technologies to make significant contributions to human health and improve quality of life through their innovative research and development initiatives.

Taiwan

HuniLife Biotechnology, Inc. is a Taiwan-based biopharmaceutical company founded in 2013. HuniLife strives to develop efficacious new drugs and treatments to improve human health and well-being. The company focuses on drug pipelines, patents, clinical trials, and investment in the biopharmaceutical industry.

Hunilife

Company Details